ABSTRACT
Background Pneumococcal conjugate vaccines (PCVs) induce serotype-specific IgG antibody, effectively reducing vaccine-serotype (VT) carriage and invasive pneumococcal disease (IPD). IgG production wanes approximately 1 month after vaccination in absence of serotype-specific exposure. With uncertainty around correlate of protection (CoP) estimates and with persistent VT carriage and VT-IPD following PCV13 introduction, we undertook population-level immunogenicity profiling among children <5 years in Blantyre, Malawi.
Methods For 638 children, capsule-specific IgG to PCV13 VTs, two non-VTs, and IgG to three pneumococcal proteins were measured using an enzyme-linked immunosorbent assay and a direct-binding electrochemiluminescence-based multiplex assay. A linear spline regression model estimated population-level, serotype-specific immunogenicity profiles. A linear regression model was used to validate putative CoPs.
Findings Immunogenicity profiles revealed a consistent pattern among VTs except serotype 3: a vaccine-induced IgG peak followed by waning to a nadir and subsequent increase in titre. For serotype 3 there was no apparent vaccine-induced increase. Heterogeneity in parameters included age range at post-vaccination-nadir (11·2 [19F, 23F] to 27·3 [7F] months). Titres dropped below IPD CoPs among 9 VTs and below carriage CoPs for 10 VTs. Study data estimated a range of carriage CoPs (0·50μg/mL to 2·5μg/mL). Increasing antibody among older children and seroincident events were consistent with ongoing VT exposure.
Interpretation A 3+0 PCV13 schedule with high uptake has not led to sustained population-level antibody immunity beyond the first year of life. Indeed, post-vaccine antibody concentrations dropped below putative CoPs for several VTs, potentially contributing to persistent VT carriage and residual VT-IPD in Malawi and other similar settings.
Funding Bill & Melinda Gates Foundation, Wellcome UK, and National Institute for Health & Care Research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Bill & Melinda Gates Foundation (OPP1117653 to RSH), a Wellcome Programme Grant (WT091909/B/10/Z to RSH), and National Institute for Health & Care Research (NIHR) Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government (16/136/46 to RSH). The Malawi-Liverpool-Wellcome Programme is supported by a Strategic Award from Wellcome, U.K. (206545/Z/17/Z). TDS, RSH and NF are supported by the NIHR Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government. The findings and the views expressed are those of the authors and not necessarily those of the NIHR or any other affiliated institutions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The pneumococcal carriage study protocol was approved by the Kamuzu University of Health Sciences (formerly College of Medicine, University of Malawi) Research and Ethics Committee and the Liverpool School of Tropical Medicine Research Ethics Committee. The serology component received ethics approval from the Oxford Tropical Research Ethics Committee, the Malawian National Health Sciences Research Committee and the Kamuzu University of Health Sciences (formerly College of Medicine, University of Malawi) Research and Ethics Committee. Parents/guardians of child participants provided written informed consent, including consent for publication.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Joint last authors
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos